GLP-1 Semaglutide shows no benefit over placebo in the Phase 3 EVOKE Alzheimer’s trial.
Автор: Hidoc Drug Info
Загружено: 2025-11-27
Просмотров: 19
Описание:
Discover doctor-approved health tips for fitness and preventing illness with Hidoc Dr.
Semaglutide, a GLP-1 agonist widely used for diabetes and obesity, did not outperform placebo in slowing Alzheimer’s progression in the phase 3 EVOKE trials. Despite this setback, biomarker improvements hint at potential future combination-therapy pathways in Alzheimer’s disease research.
Access the detailed Articles here: https://hidocdr.com/news_detailes.php
#HidocDr #HealthTips #StayHealthy #HealthCare #MedicalTips #Wellness #HealthyLiving #FitnessAndHealth #HealthyLifestyle
#AlzheimersResearch #Semaglutide #GLP1 #EVOKETrial #ClinicalTrials #NeurologyUpdates #HealthcareNews #PharmaResearch #DementiaAwareness
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![Эффект Джанибекова [Veritasium]](https://imager.clipsaver.ru/N9HlQ-XVnFk/max.jpg)
